| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Loss on legal settlements | -15,075 | - | - | - |
| Othernon-operating income, net | 8 | -207 | -157 | 2,003 |
| Totalnon-operating expense, net | -89,110 | -910,357 | 623,494 | -413,906 |
| Loss before income taxes | -146,535 | -936,641 | 580,898 | -455,125 |
| Income tax expense | 125 | 158 | 205 | 134 |
| Net loss | -146,660 | -936,799 | 580,693 | -455,259 |
| Net loss per share - basic (in dollars per share) | -0.46 | -0.04 | 1.44 | -1.17 |
| Net loss per share - diluted (in dollars per share) | -0.46 | -0.04 | 1.25 | -1.17 |
| Weighted average shares outstanding - basic (in shares) | 318,562,000 | 317,985,000 | 315,186,000 | 292,486,000 |
| Weighted average shares outstanding - diluted (in shares) | 318,562,000 | 317,985,000 | 363,314,000 | 292,486,000 |
Core Scientific, Inc. tx (CORZR)
Core Scientific, Inc. tx (CORZR)